SCHEMBL5929310

SCHEMBL5929310

CCc1cccc(CC)c1-c1nc(-c2ccc(C)cc2)c(CN2CCCCC2c2ccc(OC)cc2)n1CCOC

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ OPRM1 P35372 1/20 0.37
▸ OPRK1 P41145 1/20 0.37
▸ KDM4E B2RXH2 4/20 0.36
▸ ALDH1A1 P00352 3/20 0.36
▸ EGFR P00533 1/20 0.35
▸ DRD2 P14416 2/20 0.35
▸ DRD3 P35462 2/20 0.35
▸ MAPT P10636 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ HCRTR1 O43613 1/20 0.35
▸ HCRTR2 O43614 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ IL33 O95760 2/20 0.34
▸ THRB P10828 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5928948 0.87 OPRK1 (0.40) KMT2AMEN1OPRM1OPRK1KDM4E
SCHEMBL5929192 0.86 KMT2A (0.39) KMT2AMEN1OPRM1OPRK1KDM4E
SCHEMBL5929122 0.86 KMT2A (0.41) KMT2AMEN1KDM4EALDH1A1DRD2
SCHEMBL5929181 0.85 KMT2A (0.34) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL5929219 0.84 OPRK1 (0.40) KMT2AMEN1OPRM1OPRK1KDM4E
SCHEMBL5929073 0.84 KMT2A (0.40) KMT2AMEN1OPRM1OPRK1KDM4E
SCHEMBL5929141 0.83 KMT2A (0.38) KMT2AKDM4EALDH1A1DRD2DRD3
SCHEMBL5929002 0.80 CD274 (0.36) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL5929125 0.80 GAA (0.40) KMT2AKDM4EALDH1A1DRD2DRD3
SCHEMBL5929127 0.80 ALDH1A1 (0.35) KMT2AMEN1KDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060154917-A1 Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators NEUROGEN CORPORATION (US) 2006-07-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154917-A1 Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators C5AR1, C5AR2, C3AR1 KMT2A 2955/4885MEN1 2791/4885OPRM1 580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback